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Abstract
Routine second screening of most newborns at 8–14 days of life for a panel of newborn conditions 
occurs in 12 U.S. states, while newborns in the other states typically undergo only a single routine 
newborn screen. The study objective was to evaluate screening consequences for primary 
congenital hypothyroidism (CH) in one- and two-screen states according to laboratory practices 
and medical or biochemical characteristics of screen-positive cases. Individual-level medical and 
biochemical data were retrospectively collected and analyzed for 2,251 primary CH cases in one-
screen (CA, WI) and two-screen (AL, DE, MD, OR, TX) states. Aggregate data were collected 
and analyzed for medical and biochemical characteristics of all screened newborns in the states. 
Among the states evaluated in this study, the detection rate of primary CH was higher in the one-
screen states. In the two-screen states, 11.5% of cases were detected on the second screen. In 
multivariate analyses, only race/ethnicity was a significant predictor of cases identified on the first 
versus second screen, which likely reflects a physiologic difference in primary CH presentation. 
Newborn screening programs must heed the potential for newborns with CH not being detected by 
a single screen, particularly newborns of certain races/ethnicities. If the two-screen states 
converted to a single screen using their current algorithms, newborns currently identified on the 
routine second screen would presumably not be detected, resulting in probable delayed diagnosis 
and treatment. However, based on the one-screen state experiences, with appropriate 
modifications in screening method and algorithm, the two-screen states might convert to single 
screen operation for CH without loss in performance.
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1. Introduction
Newborn screening (NBS) has been an effective and successful public health program for 
the early detection and treatment of disorders that can cause intellectual disability, 
morbidity, and in some cases, mortality. When NBS began in the 1960s, it was typical that 
the heel stick blood specimens were obtained at 48–96 hours following birth. This practice 
lowered the chance of cases screening falsely negative from inadequate nutritional intake to 
detect metabolic abnormalities or from a physiologic delay in elevation of thyroid 
stimulating hormone (TSH) concentrations [1]. Changes in the healthcare system have 
subsequently resulted in early hospital discharge of most mothers and newborns before 48 
hours of life. Although the majority of blood specimens are collected in the 24–48 hour 
period, early discharge has significantly impacted NBS, such that many blood specimens are 
now collected before 24 hours of life [2, 3]. When only a single newborn screen is collected, 
there is an increased chance of missing cases (false-negatives), resulting in delayed 
diagnosis [4, 5]. To minimize the chance of clinically significant disorders being missed by 
a single screen, 9 states (AZ, CO, DE, NV, NM, OR, TX, UT, WY) have mandated that a 
second blood specimen be routinely collected on all newborns, preferably at 8–14 days of 
age, regardless of the results of the first routine newborn screen. An additional 3 states (AL, 
MD, WA) recommend a second screen, which is obtained at 8–14 days from birth on ≥85% 
of newborns in the state, although routine second screening was initiated in Maryland in 
1976, prior to the impact of early discharges [5]. Thus, routine second screening in these 12 
states occurs for approximately 22.5% of all U.S. newborns. Newborns in the other states 
typically undergo only a single newborn screen, although some newborns might receive a 
second screen (targeted second screening) according to state-based screening algorithms for 
preterm newborns or early specimen collection.
The evidence that a routine second screen detects clinically significant cases that would 
otherwise be missed by a single screen comes primarily from published reports by states 
performing routine second screens for primary congenital hypothyroidism (CH) and 
congenital adrenal hyperplasia (CAH) [6–11]. In spite of these reports, there has been no 
clear consensus regarding the utility of routine second screening, or whether it is the most 
appropriate public health approach to detect cases that might otherwise be missed (delayed 
diagnosis). Therefore, to evaluate the justification for the routine second screen, the Health 
and Human Services Secretary’s Advisory Committee on Heritable Disorders in Newborns 
and Children (SACHDNC) endorsed that the study described here be undertaken to 
investigate the effects of the routine second screen for primary CH [12].
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2.1. Study design and participants
Under guidance from the SACHDNC, a 5-year retrospective study was developed, with 
representation on the planning workgroup from 14 state NBS laboratories, 9 
endocrinologists representing states performing only a single screen or a routine second 
screen, and representatives from the Health Resources Services Administration, the National 
Newborn Screening and Genetics Resource Center, the Centers for Disease Control and 
Prevention, the Food and Drug Administration, the Association of Public Health 
Laboratories (APHL), the SACHDNC, Pediatrix Screening, and the Congenital Adrenal 
Hyperplasia Research Education & Support Foundation. The NBS programs that were 
invited to participate in the study included those in the 9 states that mandate collection of a 
routine second screen on all newborns, the 3 states that recommend a second screen, and 3 
states that collect only a single screen. NBS programs in 7 states agreed to and followed 
through with participation.
Participating programs were defined as “one-screen states” (CA, WI) or “two-screen states” 
(AL, DE, MD, OR, TX). All participating states received Institutional Review Board 
approval for the study. Programs submitted data on all confirmed cases of CH identified by 
the state’s NBS program during a 3–5 year period (Fig. 1), which included primary CH, 
secondary CH, hypothyroxinemia of prematurity, thyroid binding globulin deficiency, T4 
resistance, transient hypothyroidism, and uncertain hypothyroidism. Data analyses in this 
report were restricted to cases of primary CH.
2.2. NBS methodologies and algorithms for CH
The NBS programs utilized different methodologies and algorithms for identifying potential 
cases of CH (Fig. 2). Three participating programs (CA, DE, WI) quantified TSH only as the 
analytic marker for CH, and all used a fixed cutoff with some minor variations based on the 
age of the newborn at the time of specimen collection. Three programs (MD, OR, TX), 
quantified thyroxine (T4) as the primary analytic marker and reflexed to analyze TSH if the 
T4 level was below the screening cutoff; 2 of these programs used fixed cutoffs for T4 and 
TSH while one program used a fixed cutoff for TSH, but for T4 used a floating cutoff that 
was determined daily based upon a percent from the mean T4 value obtained on the entire 
population of newborns screened that day. The other participating program (AL) quantified 
both T4 and TSH on all newborns, using fixed cutoffs for both analytic markers.
2.3. Data elements
NBS programs were asked to submit individual-level de-identified data on each confirmed 
cases of CH to the APHL, which served as the repository for submitted data. A secure web-
based portal developed by APHL was used for entering data elements, including the 
newborn’s demographics (e.g., race/ethnicity, sex); factors that might affect the screening 
result (e.g., age at specimen collection, birth weight (BW), neonatal intensive care unit 
(NICU) admission, blood transfusion); laboratory factors (e.g., time from screening to 
laboratory assay, screening methods, screening algorithm); and clinical characteristics 
pertaining to case diagnosis (e.g., confirmatory serum test results, thyroid imaging results, 
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treatment and when initiated, presence of birth defects, Down syndrome, or other medical 
conditions, mode of delivery, topical iodine, dopamine, or steroid exposures, family history 
of thyroid disease). Each newborn’s race/ethnicity was recorded on each state’s NBS blood 
collection card, and was designated at the time of specimen collection. NBS programs also 
reported the CH type diagnosed for each case, and whether each case was identified on the 
first screen, second screen, or was a case not detected by NBS. Due to this being a 
retrospective study, data from states were missing some data elements. Therefore, only the 
following variables could be included in analyses: state, race/ethnicity (non-Hispanic white 
(NHW), non-Hispanic black (NHB), Hispanic, Asian/Pacific Islander (A/PI), Other), sex 
(male, female), feeding status at the time of first screen (breastfeeding only, formula only, 
breastfeeding and formula, total parenteral nutrition (TPN), other), BW (<1000 g, 1000–
2499 g, 2500–3999 g, ≥4000 g), NICU admission at time of first screen (no, yes), blood 
transfusion prior to first screen (no, yes), age of newborn at first screen specimen collection 
(0 days, 1 day, 2 days, 3 days, ≥4 days), time from first screen specimen collection to 
laboratory assay completion (0–3 days, 4–5 days, 6–7 days, ≥8 days), and initial abnormal 
screen identifying the potential case (first screen, second screen—for the two-screen states), 
targeted second screen (for the one-screen states), detected clinically (i.e., no abnormal 
screening result(s)). A metabolic specialist (S.K.S.) reviewed all submitted data to confirm 
the initial abnormal screen identifying the potential case and the diagnosis as primary CH.
In addition to the above data on confirmed primary CH cases, NBS programs submitted 
aggregate data on all newborns screened during the time periods shown in Fig. 1 for the 
following variables: race/ethnicity, sex, feeding status at the time of first screen, BW, NICU 
admission at time of first screen, blood transfusion prior to first screen, age of newborn at 
first screen specimen collection, and time from first screen specimen collection to laboratory 
assay completion. Additionally, the two-screen states submitted aggregate data for race/
ethnicity for all newborns receiving a routine second screen.
2.4. Data analysis
The total number of newborns screened and the number screened with each characteristic 
were used to calculate estimated detection rates of cases in the one- and two-screen states. 
The numerator for each detection rate was the number of identified primary CH cases with 
the characteristic, and the denominator was the number of all screened newborns with the 
same characteristic. Detection rates overall and for each characteristic were compared 
between the one-screen and two-screen states by Z-test for 2 proportions.
The variables described in section 2.3. Data elements were evaluated by univariate analyses 
for inclusion in logistic regression models as predictive of a case of primary CH being 
identified in the two-screen states on the initial abnormal screen (first screen versus the 
second screen). Predictive modeling was then conducted with the significant variables using 
multivariate logistic regression and assessing which factors remained significantly 
associated with the initial abnormal screen after adjusting for other covariates.
For confirmed cases of primary CH in both the one- and two-screen states, TSH screening 
concentrations were log-transformed and compared between race/ethnicity categories using 
least squares means, adjusting for state, sex, BW (as a continuous variable), blood 
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transfusion prior to first screen, and age of newborn at first screen specimen collection. 
Analyses for cases identified on first screens or second screens were conducted separately. 
Adjusted means for the transformed serum TSH concentrations for each race/ethnicity were 
then untransformed for data presentation. Cases from Maryland were excluded from the 
analyses because the program reported BW as a categorical variable, in contrast to the other 
states that reported the individual BW values. Logistic regression and least squares means 
analyses were conducted using SAS 9.3 (SAS Institute, Inc., Cary, NC).
3. Results
3.1. One-screen versus two-screen states
Data for a total of 1056 cases of primary CH were submitted by the one-screen states and 
1195 cases by the two-screen states (Table 1). Cases were identified by an abnormal 
newborn screen result on either the first screen, routine second screen (two-screen states), or 
targeted second screen (one-screen states). Cases were classified as unknown if an initial 
specimen submitted for NBS was deemed unsatisfactory by the laboratory and the case was 
detected on a subsequent screening specimen, but because of the initial unsatisfactory 
specimen, it is unknown whether the case would have been detected on the first screen. A 
small proportion of cases in both the one- and two-screen states were not identified by NBS, 
but were identified clinically and were subsequently reported to the NBS programs.
In the one-screen states, 1027 cases of primary CH (97.2%) were identified on the first 
screen, 19 cases (1.8%) were detected on a targeted second screen, and the remaining 10 
cases were either unknown or not detected by NBS (Table 1). Based on the total of 
2,010,531 newborns screened on the first screen in one-screen states, the detection rate of 
cases detected on the first screen was 1 in 1,958 and the overall detection rate for all cases of 
primary CH in one-screen states was 1 in 1,904. In the two-screen states, 1041 cases of 
primary CH (87.1%) were identified on the first screen, 137 cases (11.5%) were detected on 
the second screen, and the remaining 17 cases were either unknown or not detected by NBS 
(Table 1). Based on the total of 2,629,627 newborns screened on the first screen in the two-
screen states, the detection rate of cases detected on the first screen was 1 in 2,526, and the 
detection rate for those detected initially on the routine second screen was 1 in 19,194. The 
overall detection rate for primary CH in the two-screen states was 1 in 2,201.
The detection rate for primary CH overall was significantly higher in the one-screen than in 
the two-screen states evaluated in this study (p=0.001) (Table 2). This difference was 
primarily accounted for by a higher detection rate in the one-screen states among NHW 
newborns (p=0.038), female newborns (p<0.001), and among normal BW newborns 
(p=0.009); there was also a higher detection rate among Hispanic newborns, but it was 
borderline non-significant (p=0.056). Additionally, the primary CH detection rate was 
higher in the one-screen states for newborns whose NBS specimen was collected at <24 
hours of life (p=0.010) or at 24–47 hours (p<0.001).
Further investigation of this difference in the detection rate of primary CH related to age of 
specimen collection showed that the mean age of first specimen collection for primary CH 
cases detected on the first screen was significantly lower in the one-screen than in the two-
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screen states (Table 3); this difference was statistically significant for each racial/ethnic 
group and overall.
No difference in detection rate was found for NHB or male newborns, newborns in the 
NICU when the first screen was collected, and newborns that were very low BW (<1000 g) 
or low BW (1000–2499 g) (Table 2). Several characteristics had a lower primary CH 
detection rate among newborns in the one-screen states: A/PI race (p=0.001), blood 
transfusion prior to the first NBS specimen collection (p=0.023), and NBS specimen 
collected at ≥96 hours of life (p<0.001) (Table 2).
The detection rate of primary CH differed by racial/ethnic group (Table 2). The highest 
detection rate of primary CH was found among A/PI and Hispanic newborns, followed by 
newborns in the Other race/ethnicity category and NHW newborns. NHB newborns had the 
lowest detection rate of primary CH. The race/ethnicity makeup of the screened populations 
differed between the one- and two-screen states. Among all screened newborns, there was a 
higher proportion of Hispanic (44% vs. 35%) and A/PI (8% vs. 3%) newborns and a lower 
proportion of NHW (34% vs. 41%) and NHB (6% vs. 14%) newborns in the one-screen 
states, compared with the two-screen states.
3.2. First screen versus second screen: two-screen states
In unadjusted analyses, numerous characteristics differed between cases detected on the first 
versus the second screen in the two-screen states (Table 4). First-screen cases (compared to 
second-screen cases) were less likely to be detected in Maryland and Oregon than in Texas 
(odds ratio (OR)=0.33; 95% confidence interval (CI)=0.19–0.56 and OR=0.44; 95% 
CI=0.26–0.75, respectively); less likely to be NHB or A/PI newborns than NHW newborns 
(OR=0.40; 95% CI=0.22–0.73 and OR=0.21; 95% CI=0.11–0.37, respectively); less likely 
to be very low BW (<1000 g) than to be normal BW (2500–3999 g) (OR=0.42; 95% 
CI=0.20–0.88); less likely to have received a blood transfusion before the first newborn 
screen (OR=0.43; 95% CI=0.19–0.97); more likely to be female than male (OR=1.51; 95% 
CI=1.05–2.16); and more likely to have had the first NBS specimen collected at 24–47 hours 
of life than collected at <24 hours (OR=2.06; 95% CI=1.26–3.35).
In multivariate logistic regression only race/ethnicity was significant, with NHB and A/PI 
newborns less likely than NHW newborns to be identified on the first versus second screen 
(Table 4). There was no significant difference for Hispanic newborns or newborns in the 
Other race/ethnicity category, compared with NHW newborns (OR=1.33; 95% CI=0.84–
2.13, OR=0.49; 95% CI=0.20–1.18, respectively).
To investigate these race/ethnicity differences further between cases identified on the first 
versus the second screen in the two-screen states, least square means analyses, stratified by 
race/ethnicity, were conducted for the TSH screening concentrations of the cases reported by 
the NBS programs (right side of Fig. 3).
Geometric mean TSH serum concentrations were adjusted for the variables reported in 
Table 4 that were significant predictors for cases being identified on the first versus the 
second screen in univariate analyses. The race/ethnicity groups were NHW, NHB, Hispanic, 
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and Other, which included A/PI, Middle Eastern, Native American, and Other, non-
specified. Among the cases in the Other category, 66% of first-screen cases and 85% of 
second-screen cases were A/PI. For first screen cases, the adjusted geometric mean TSH 
concentrations were significantly lower for NHB newborns, compared with NHW newborns 
(p<0.001) and Hispanic newborns (p<0.001); there was no significant difference for NHB 
compared with Other (p=0.062). For the second screen, the adjusted geometric mean TSH 
concentrations were still significantly lower for NHB newborns compared with NHW 
newborns (p=0.002) and Hispanic newborns (p<0.001), and there was no significant 
difference for NHB compared with Other (p=0.080). In order to confirm that the pattern of 
geometric means by race/ethnicity was not unique to the two-screen states, a similar least 
square means analysis was performed on cases identified on the first screen in one-screen 
states (left side of Fig. 3). For the cases in the Other category, 77% were A/PI. Similar to the 
two-screen states, the adjusted geometric mean TSH concentrations in the one-screen states 
were significantly lower for NHB newborns, compared with NHW newborns (p=0.006) and 
Hispanic newborns (p<0.001), and in this case also significantly lower when compared with 
Other newborns (p=0.002).
4. Discussion
Among the two-screen states evaluated in this study, 11.5% of primary CH cases were 
detected on the routine second screen, which is comparable to rates of second-screen 
identified cases in previous single state studies: 10.4% in the Northwest Regional Screening 
Program [9], 5.1% in Texas [13], 7.7% in Washington state [7], and 18.5% in Colorado [10]. 
All of the cases detected on the routine second screen in the current study appear to have 
been clinically significant since they were treated with thyroid replacement therapy. If the 
two-screen states performed only a single screen according to their current screening 
algorithms, these cases would not have been detected by the NBS programs since the first 
screen results for these cases were normal.
The only statistically significant predictor in multivariate analysis for identifying cases on 
the first screen compared to the second screen in the two-screen states was race/ethnicity. 
Compared to cases identified on the second screen, the first screen cases were less likely to 
be NHB or A/PI, than to be NHW cases. These race/ethnicity differences in detection on 
first versus second screen appear to be due to differences in the physiologic responses of the 
hypothalamic-pituitary axis to the hypothyroid state. Among cases in the two-screen states, 
NHB newborns, as well as newborns in the Other race/ethnicity category (primarily A/PI), 
had significantly lower serum TSH concentrations on NBS assays compared with NHW and 
Hispanic newborns. These differences were present for both first- and second-screen 
identified cases. For cases in the one-screen states, NHB newborns also had significantly 
lower serum TSH concentrations on NBS assays compared with newborns in all other racial/
ethnic groups. These findings suggest that the TSH rise in response to low T4 in NHB and 
probably A/PI newborns is perhaps not as early or as elevated as among NHW and Hispanic 
newborns, which might account for the higher proportion of NHB and A/PI newborns being 
identified on the routine second screen in the two-screen states. Given these physiologic 
differences in biochemical presentation of primary CH, it appears that the routine second 
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screen is an effective way to detect these cases that might otherwise be missed by a single 
screen.
Among the states evaluated in this study, the overall detection rate of primary CH was 
significantly higher in the one-screen states compared with the two-screen states. Newborns 
with certain characteristics had a significantly higher detection rate in the one-screen states: 
NHW, female, normal BW, or being screened at <48 hours of life. It is unlikely that a single 
explanation accounts for these differences, although the different detection rates of primary 
CH for the race/ethnicity groups could be a significant contributing factor to the overall 
detection rate of primary CH being higher in the one-screen states. Previous studies have 
reported that compared to NHW newborns, primary CH is more common among Hispanic 
and A/PI newborns, and less common among NHB newborns [14–19]. The analyses 
performed here showed similar relationships between detection rates by race/ethnicity 
(Table 2). The populations screened by the one- and two-screen states differed by race/
ethnicity, with higher proportions of the screened populations being Hispanic and A/PI in 
the one-screen, compared to the two-screen states. Since newborns in these 2 racial/ethnic 
groups have a higher detection rate of primary CH, compared with NHW and NHB 
newborns, the higher Hispanic and A/PI makeup of the screened population in the one-
screen states likely contributes in part to the higher primary CH detection rate in the one-
screen states. However, that cannot be the entire explanation because if race/ethnicity were 
the only factor predicting the primary CH detection rate, then the detection rate among each 
racial/ethnic group should be the same in the one- and two-screen states; contrary to this, the 
observed primary CH detection rate was significantly higher among NHW newborns, 
borderline higher among Hispanic newborns, and significantly lower among A/PI newborns 
in the one-screen states compared with the two-screen states. Therefore, other factors are 
also impacting the primary CH detection rate differences between the one- and two-screen 
states, Unfortunately it is not possible to examine these factors independently since 
individual-level data on all screened newborns was not available.
The significantly different primary CH detection rates between the one-and two-screen 
states could also be related in part to screening methodologies, which are notably different 
between the states. Both of the one-screen states only assay TSH as the screening analytic 
marker, while among the two-screen states, DE assays only TSH, AL assays both T4 and 
TSH, and the other two-screen states assay T4 as the primary analytic marker, with a reflex 
to TSH if the T4 concentration is below a specific screening cutoff. If the differences in 
screening methods caused the lower identified detection rate in the two-screen states, this 
would suggest that even with a routine second screen on the majority of newborns, a large 
number of cases were not detected in the two-screen states. However, there is no evidence 
for a large number of cases in these states not being detected by screening. Therefore, 
although screening methodologies differed between the one- and two-screen states, it is 
unlikely that screening methods in the two-screen states account in a substantial way for the 
lower detection rate.
Another potential cause for detection rate differences might be misclassification. For 
example, if substantially more cases of transient hypothyroidism were misdiagnosed as 
primary CH in the one-screen states, this might inflate the observed detection rate. Since the 
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female-to-male ratio for primary CH is approximately 2:1, and for transient hypothyroidism 
it is on the order of 0.5:1 to 1:1 [20–22], if a significant number of newborns with transient 
hypothyroidism were misclassified as primary CH, then the observed ratio would fall below 
2:1. However, among the cases in the one-screen states, the sex ratio is 2.17:1, indicating 
that there is unlikely to have been substantial misclassification of this type to inflate the 
detection rate. Another potential source of misclassification involves the diagnoses assigned 
to 2 groups of newborns in the two-screen states: 209 newborns with hypothyroxinemia of 
prematurity and 93 newborns with uncertain hypothyroidism (compared to only 1 and 28 
newborns, respectively reported as being in these 2 groups in the one-screen states). The 
former group consists of preterm newborns treated for hypothyroidism because of low T4, 
but generally normal TSH concentrations [23–25]. The latter group consists of newborns 
without a specific confirmatory diagnosis and some may not actually have hypothyroidism. 
These newborns did not have primary CH according to the data provided by the state 
laboratories, so they were excluded from the study. However, if enough newborns in these 2 
groups actually had primary CH, but were misclassified as hypothyroxinemia of prematurity 
or uncertain hypothyroidism because of insufficient follow-up testing, that misclassification 
could have erroneously lowered the observed detection rate for primary CH in the two-
screen states. One final source of misclassification might be related to the age of the 
newborn at the time of the initial specimen collection. Compared to the two-screen states, 
cases identified on the first screen in the one-screen states had (1) higher geometric mean 
TSH concentrations (Fig. 3), (2) specimens collected on average at a younger age (1.25 days 
vs. 2.34 days; Table 3), and (3) a higher overall rate of detected cases among those 
newborns with specimens collected at <48 hours of life (Table 2). These observations 
suggest that the time of specimen collection might impact the case detection rate since 
newborns undergoing earlier collection of specimens, closer to the TSH surge that occurs 30 
minutes following birth, would more likely be screen-positive. Although screening closer to 
birth has the potential to increase the false-positive detection rate, the CH cases reported by 
each NBS program were cases subsequently confirmed by serum diagnostic testing. Since it 
is unlikely that the one-screen states have misclassified false-positive cases as actual cases, 
this potential source of misclassification does not seem related to the higher detected rate in 
the one-screen states.
Finally, less than 15% of primary CH cases have a known genetic basis [26–30], so the 
underlying causes for most cases remain unknown. If the observed primary CH detection 
rates reflect a true difference between the one- and two-screen states, then these rates could 
mirror the causes of primary CH from yet undetermined genetic factors and environmental 
exposures that differ between the populations of the one- and two-screen states evaluated in 
this study.
A limitation of this study is the retrospective data collection; data were incomplete for 
certain variables since the NBS laboratories and follow-up programs could only report the 
data that were available. Additionally, results could be biased by the states that contributed 
the largest number of cases. Furthermore, results and conclusions are not generalizable to all 
one-screen and two-screen states, but are limited to those that participated in this study. 
Another limitation is that the diagnosis of primary CH was not necessarily determined after 
adequate follow-up to differentiate between permanent and transient hypothyroidism. 
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Finally, the CH screening protocols, including the screening methods, screening analytic 
marker cutoffs, and screening algorithms differed between the laboratories, with some even 
instituting protocol changes during the course of the study; therefore, direct comparison of 
the effects of laboratory screening protocols on primary CH detection rates was not possible. 
The strengths of this study are that it is the only comparative study between one-screen and 
two-screen states; the sample included 2,251 cases of primary CH from among 4.64 million 
births, which is much larger than the previously reported within-state studies [7, 9, 10, 13]; 
and individual-level data for cases improved the ability to tease out specific associations.
5. Conclusion
Due to significant differences in screening algorithms between the one- and two-screen 
states evaluated in this study, it is not possible to make conclusions about the comparative 
utility of a routine second screen in contrast to a single newborn screen. However, it is 
notable that in the two-screen states, 11.5% of all primary CH cases were detected on the 
routine second screen and race/ethnicity of the newborn played a significant role in 
predicting whether a case would be identified on the first versus the second screen, with 
NHB and A/PI newborns more likely identified on the routine second screen compared with 
NHW and Hispanic newborns. Therefore, NBS programs that perform only a single 
newborn screen for primary CH must be aware of the potential for affected newborns not 
being detected by the single screen, particularly newborns of certain races/ethnicities. If the 
two-screen states converted to a single screen using their current NBS algorithms, the 
second screen-positive primary CH cases that they currently identify would presumably not 
be detected, resulting in probable delays in diagnosis and treatment. On the other hand, there 
is no evidence that the one-screen states, by not performing a routine second screen, are 
missing a substantial number of cases, since the overall primary CH detection rate in the 
one-screen states was found to be higher than in the two-screen states, and the one-screen 
states are aware of only a tiny proportion (<1%) of the primary CH cases not being detected 
by NBS. Therefore, with appropriate modifications in screening method and algorithm to 
align more closely with the processes in the one-screen states, the two-screen states might 
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Source of cases of congenital hypothyroidism by year.
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Congenital hypothyroidism screening algorithm for each state.
T4=thyroxine; TSH=thyroid stimulating hormone
Shapira et al. Page 15














Adjusteda mean newborn screening TSH screening concentrations by race/ethnicity for 
primary CH cases identified on the first screen in one-screen states, and on the first or the 
second screen in two-screen states.
aAdjusted for state, sex, birth weight, blood transfusion prior to first screen, and age of 
newborn at first screen specimen collection
TSH=thyroid stimulating hormone; CH=congenital hypothyroidism; NHB=non-Hispanic 
black; NHW=non-Hispanic white
Other includes Asian/Pacific Islander, Middle Eastern, Native American, and Other, non-
specified
Error bars specify the standard deviation
P-values are shown for non-Hispanic black compared with the other racial/ethnic groups
*P < 0.001; **P = 0.002; ***P = 0.006
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Table 1






First Screen 1027 (97.2) 1041 (87.1)
Second Screen NA 137 (11.5)
Targeted Second Screen 19 (1.8) NA
Unknowna 2 (0.2) 12 (1.0)
Not Detected by NBS 8 (0.8) 5 (0.4)
TOTAL 1056 (100) 1195 (100)
a
Unknown cases had an initial specimen submitted for NBS that was deemed unsatisfactory by the laboratory; the case was detected on a 
subsequent screening specimen, but because of the initial unsatisfactory specimen, it is unknown whether the case would have been detected on the 
first screen.
N=number; NA=not-applicable; NBS=newborn screening













Shapira et al. Page 18
Table 2




Detection Rate of Primary 
CH (1 in N)
Two-Screen States 
Detection Rate of Primary 
CH (1 in N) P-valuea
Race/Ethnicity
Non-Hispanic White 2240 2621 0.038
Non-Hispanic Black 3441 3932 0.499
Hispanic 1573 1767 0.056
Asian/Pacific Islander 1586 968 0.001
Other 1893 2637 0.168
Sex
Male 2988 2987 0.998
Female 1375 1734 <0.001
Birth Weight
<1000 g 2101 324 0.209
1000–2499 g 3431 1247 0.373
2500–3999 g 1714 2314 0.009
≥4000 g 1623 1965 0.893
NICU Admission
Yes 915 908 0.942
No 2062 2374 0.003
Blood Transfusion
Yes 560 225 0.023
No 1766 2029 0.002
Age at Specimen Collection (first screen)
0 days (<24 hours) 1767 2493 0.010
1 day (24–47 hours) 2063 3478 <0.001
2 days (48–71 hours) 1802 1508 0.087
3 days (72–95 hours) 1884 1445 0.248
≥ 4 days (≥ 96 hours) 968 554 <0.001
Overall 1904 2201 0.001
a
Based on Z-test for 2 proportions; significant p-values are shown in bold font
CH=congenital hypothyroidism; N=number; NICU=neonatal intensive care unit
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Table 4





Identified on the First vs. Second Screen in the Two-Screen States
Univariate Full Model Predictive Model
OR (95% CI) OR (95% CI) OR (95% CI)
State
 Texas 868 (73.7%) Reference Reference
 Alabama 94 (8.0%) 1.35 (0.61–3.01) 2.02 (0.81–5.04)
 Delaware 21 (1.8%) 0.65 (0.19–2.26) 0.93 (0.23–3.82)
 Maryland 89 (7.5%) 0.33 (0.19–0.56) 0.60 (0.28–1.31)
 Oregon 106 (9.0%) 0.44 (0.26–0.75) 0.72 (0.32–1.64)
Race/Ethnicity
 Non-Hispanic White 405 (36.2%) Reference Reference Reference
 Non-Hispanic Black 90 (8.0%) 0.40 (0.22–0.73) 0.45 (0.23–0.88) 0.40 (0.22–0.73)
 Hispanic 512 (45.8%) 1.33 (0.84–2.13) 1.09 (0.66–1.80) 1.33 (0.84–2.13)
 Asian/Pacific Islander 73 (6.5%) 0.21 (0.11–0.37) 0.22 (0.12–0.40) 0.21 (0.11–0.37)
 Other 39 (3.5%) 0.49 (0.20–1.18) 0.45 (0.17–1.19) 0.49 (0.20–1.18)
Sex
 Male 436 (37.7%) Reference Reference
 Female 722 (62.3%) 1.51 (1.05–2.16) 1.26 (0.84–1.88)
Feeding Status
 Breastfeeding Only 404 (38.1%) Reference
 Breastfeeding and Formula 277 (26.1%) 1.22 (0.77–1.96)
 Formula Only 278 (26.2%) 1.38 (0.85–2.24)
 TPN 83 (7.8%) 1.13 (0.55–2.32)
 Other 19 (1.8%) 0.43 (0.15–1.25)
Birth Weight
 <1000 g 43 (3.8%) 0.42 (0.20–0.88) 1.05 (0.36–3.07)
 1000–2499 g 134 (11.7%) 0.88 (0.51–1.52) 0.97 (0.52–1.83)
 2500–3999 g 886 (77.3%) Reference Reference
 ≥4000 g 83 (7.2%) 1.99 (0.79–5.02) 1.63 (0.62–4.26)
NICU Admission
 No 939 (80.7%) Reference
 Yes 225 (19.3%) 0.69 (0.45–1.05)
Blood Transfusion
 No 1063 (97.0%) Reference Reference
 Yes 33 (3.0%) 0.43 (0.19–0.97) 0.60 (0.21–1.67)
Age of Newborn at Collection
 0 days 66 (5.6%) Reference Reference

















Identified on the First vs. Second Screen in the Two-Screen States
Univariate Full Model Predictive Model
OR (95% CI) OR (95% CI) OR (95% CI)
 1 day 444 (38.1%) 2.02 (1.03–3.98) 1.50 (0.77–2.91)
 2 days 465 (39.9%) 1.87 (0.96–3.65) 1.38 (0.69–2.77)
 ≥3 days 191 (16.4%) 1.88 (0.89–4.00) 1.08 (0.49–2.38)
Time from Collection to Assay
 0–3 days 251 (21.3%) Reference Reference
 4–5 days 356 (30.2%) 2.27 (1.40–3.69) 1.54 (0.80–2.97)
 6–7 days 368 (31.3%) 2.01 (1.26–3.20) 1.26 (0.64–2.50)
 ≥8 days 203 (17.2%) 1.76 (1.02–3.01) 0.93 (0.43–2.02)
CH=congenital hypothyroidism; OR= odds ratio; CI=confidence interval; N=number; TPN=total parenteral nutrition; NICU=neonatal intensive 
care unit
Significant odds ratios are shown in bold font
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